Coridon HSV-2 vaccine shows 100% efficacy

Tools

Brisbane, Australia-based biotech Coridon has developed a DNA vaccine for herpes simplex virus 2 that showed 100% efficacy in a preclinical trial. Thanks to financial backing from Allied Healthcare Group, Coridon hopes to push the vaccine into human trials in the next year. As a DNA vaccine, the HSV-2 vax can be used both for preventative and curative measures. Article

Filed Under
Coridon, ,

Comments